THOUSAND OAKS, Calif.--(BUSINESS WIRE)--July 1, 2004--Amgen Inc.
(Nasdaq:AMGN), the world´s largest biotechnology company, today
announced the appointment of Joshua Ofman, M.D., M.S.H.S., to the new
position of vice president, Reimbursement and Payment Policy. As of
today, Ofman will be responsible for the design and execution of
Amgen´s reimbursement and payment strategy and will help to ensure the
integration of reimbursement needs into the product development and
"Josh is an acknowledged physician expert in health economics and
a respected member of the health care policy world," said David Beier,
Amgen´s senior vice president, Global Government Affairs. "In this new
role, Josh is leading the effort to ensure that patients have access
to Amgen´s products and that payors, especially governments,
understand the value proposition that our products represent."
Ofman joined Amgen in 2003 as senior director, U.S. Medical
Affairs, and head of Amgen´s U.S. Health Economics and Outcomes
Research group. Prior to joining Amgen, Ofman was an academic
gastroenterologist at Cedars-Sinai Health System and senior vice
president of Zynx Health, Inc., a subsidiary of Cerner Corp., a
publicly traded healthcare information technology company. Ofman
obtained his undergraduate degree from the University of California at
Berkeley and his M.D. from the University of California, Irvine
College of Medicine. He conducted his internship and residency in
internal medicine, and fellowship in digestive diseases at the
University of California, Los Angeles (UCLA) Department of Medicine.
In addition, Ofman completed a RAND/VA/UCLA fellowship in ambulatory
care and health services research, specializing in technology
assessment, and received a Masters of Science in Health Services from
the UCLA School of Public Health.
Amgen is a global biotechnology company that discovers, develops,
manufactures and markets important human therapeutics based on
advances in cellular and molecular biology and medicinal chemistry.
Mary Klem, 805-447-4587 (media)
SOURCE: Amgen Inc.